Ongoing challenges of using immunotherapy in special populations: Poor performance status patients, elderly patients, and people living with HIV
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference31 articles.
1. Prevalence of poor performance status in lung cancer patients: implications for research;Lilenbaum;J. Thorac. Oncol.,2008
2. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy;Inoue;J. Clin. Oncol.,2009
3. Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401);Iwama;J. Thorac. Oncol.,2017
4. CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS2 and elderly population;Felip;Eur. J. Cancer,2020
5. Pembrolizumab in patients with non-small-cell lung cancer of performans status 2 (PePS2): a single arm, phase 2 trial;Middleton;Lancet Respir. Med.,2020
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The increasing prevalence of cancer in the elderly: An investigation of epidemiological trends;AGING MEDICINE;2024-08
2. The safety and efficacy of PD-1 inhibitors in patients with advanced cancers and HIV/AIDS in China;Frontiers in Oncology;2023-09-19
3. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study;The Lancet;2023-08
4. Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients;Frontiers in Oncology;2022-11-07
5. Exploring the application of immunotherapy against HIV infection in the setting of malignancy: A detailed review article;International Immunopharmacology;2022-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3